Sentinel lymph node biopsy using dye alone method is reliable and accurate even after neo-adjuvant chemotherapy in locally advanced breast cancer - a prospective study

World Journal of Surgical Oncology

Volumn 9, Issue , 2011, Pages

  Chintamani, ^a   Tandon, Megha ^a   Mishra, Ashwani ^a,b   Agarwal, Usha ^a,b   Saxena, Sunita ^a,b  

^a SAFDARJUNG HOSPITAL   (India)

^b SAFDARJUNG HOSPITAL CAMPUS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHYLENE BLUE; ANTINEOPLASTIC AGENT; COLORING AGENT; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; LOCALLY ADVANCED BREAST CANCER; LYMPH NODE DISSECTION; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AXILLA; BREAST TUMOR; FEMALE; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COLORING AGENTS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; METHYLENE BLUE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

EID: 79551687006     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-9-19     Document Type: Article

References (26)

1. Cure H, Amat S, Penault-Llorca F, le Bouëdec G, Ferrière JP, Mouret-Reynier MA, Kwiatkowski F, Feillel V, Dauplat J, Chollet P. Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy. Breast Cancer res Treat 2002, 76:37-45. 10.1023/A:1020274709327, 12408374.
2. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, Binkley SM, Ames FC, Feig BW, Ross MI, Hortobagyi GN, Singletary SE. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease free survival in patients with locally advanced breast cancer. Am J Surg 1998, 176:502-9. 10.1016/S0002-9610(98)00253-0, 9926779.
3. Rouzier R, Extra JM, Klijanienko J, Falcou MC, Asselain B, Vincent-Salomon A, Vielh P, Bourstyn E. Incidence and prognostic signioficance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002, 20:1304-10. 10.1200/JCO.20.5.1304, 11870173.
4. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD. Effect of pre-operative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672-2685.
5. Van der Hage JA, Van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L, van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organisation for Research and Treatment of Cancer trial 10902. J Clin Oncol 2002, 19:4224-37.
6. Mauri D, Pavlisdis N, Ioannidis JP. Neoadjuvant vs adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:188-94. 10.1093/jnci/dji021, 15687361.
7. Mieog JS, Van der Hage JA, Van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 2007, 94:1189-2000. 10.1002/bjs.5894, 17701939.
8. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV. Effect of preoperative chemotherapy on loco-regional disease in women with operable breast cancer: findings from NSABP B-18. J Clin Oncol 1997, 15:2483-93.
9. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R, Rilke F. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990, 82:1539-45. 10.1093/jnci/82.19.1539, 2402015.
10. Fisher B, Mamounas EP. Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 1995, 13:537-40.
11. Rietman JS, Dijkstra PU, Geertzen JH, Baas P, de Vries J, Dolsma WV, Groothoff JW, Eisma WH, Hoekstra H. Treatment related upper limb morbidity 1 year after sentinel node biopsy or axillary lymph node dissection for stage I or II breast cancer. Ann Surg Oncol 2004, 11:1018-24. 10.1245/ASO.2004.03.512, 15525832.
12. Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000, 88:608-14. 10.1002/(SICI)1097-0142(20000201)88:3<608::AID-CNCR17>3.0.CO;2-K, 10649254.
13. Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, Ross MI, Buzdar AU, Hortobagyi GN, Singletary SE. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999, 230:72-8. 10.1097/00000658-199907000-00011, 1420847, 10400039.
14. Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, Bear HD, Caldwell CB, Walker AP, Mikkelson WM, Stauffer JS, Robidoux A, Theoret H, Soran A, Fisher B, Wickerham DL, Wolmark N. Sentinel node biopsy after neo-adjuvant chemotherapy in chemotherapy in breast cancer: results from NSABP protocol B-27. J Clin Oncol 2005, 23:2694-702. 10.1200/JCO.2005.05.188, 15837984.
15. Xing Y, Foy M, Cox DD. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2006, 93:539-46. 10.1002/bjs.5209, 16329089.
16. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S, Beitsch P. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 1998, 339:941-6. 10.1056/NEJM199810013391401, 9753708.
17. Tafra L, Lannin DR, Swanson MS, Tafra L, Lannin DR, Swanson MS, Van Eyk JJ, Verbanac KM, Chua AN, Ng PC, Edwards MS, Halliday BE, Henry CA, Sommers LM, Carman CM, Molin MR, Yurko JE, Perry RR, Williams R, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 2001, 233:51-59. 10.1097/00000658-200101000-00009, 1421166, 11141225.
18. McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, Vennekotter DJ, Turk PS, Tate PS, Sardi A, Cerrito PB, Edwards MJ. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000, 18:2560-6.
19. Tanis PJ, Nieweg OE, Hart AA, Kroon BB. The illusion of the learning phase for lymphatic mapping. Ann surg Oncol 2002, 9:142-7. 10.1007/BF02557365, 11888870.
20. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Singletary SE, Buzdar AU, Hortobagyi GN, Hunt KK, et al. Sentinel lymph node is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000, 18:3480-3486.
21. Nason KS, Anderson BO, Byrd DR, Dunnwald LK, Eary JF, Mankoff DA, Livingston R, Schmidt RA, Jewell KD, Yeung RS, Moe RE. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000, 89:2187-2194. 10.1002/1097-0142(20001201)89:11<2187::AID-CNCR6>3.0.CO;2-#, 11147588.
22. Julian TB, Patel N, Dusi D, Olson P, Nathan G, Jasnosz K, Isaacs G, Wolmark N. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J surg 2001, 182:407-410. 10.1016/S0002-9610(01)00736-X, 11720681.
23. Fernández A, Cortés M, Benito E, Azpeitia D, Prieto L, Moreno A, Ricart Y, Mora J, Escobedo A, Martín Comín J. Gamma probe sentinel node localization and biopsy in breast cancer patient treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun 2001, 22:361-366.
24. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenopathy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast carcinoma. Ann Surg Oncol 2002, 9:235-242. 10.1007/BF02573060, 11923129.
25. Haid A, Tausch C, Lang A, Lutz J, Fritzsche H, Peschina W, Breitfellner G, Sega W, Aufschnaiter M, Sturn H, Zimmermann G. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma?. Cancer 2001, 92(5):1080-4. 10.1002/1097-0142(20010901)92:5<1080::AID-CNCR1423>3.0.CO;2-1, 11571718.
26. Miller AR, Thomason VE, Yeh IT, Alrahwan A, Sharkey FE, Stauffer J, Otto PM, McKay C, Kahlenberg MS, Phillips WT, Cruz AB. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 2002, 9:243-247. 10.1007/BF02573061, 11923130.